Comparative Pharmacology
Head-to-head clinical analysis: BYDUREON versus CYCLOSET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BYDUREON versus CYCLOSET.
BYDUREON vs CYCLOSET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Cycloset (bromocriptine mesylate) is a dopamine D2 receptor agonist. It improves glycemic control in type 2 diabetes by resetting hypothalamic circadian rhythms, thereby reducing hepatic glucose production and increasing insulin sensitivity. It also suppresses the release of very low-density lipoprotein from the liver.
2 mg subcutaneously once every 7 days (weekly).
1.6 mg to 2.4 mg administered orally once daily at bedtime. Titrate by 0.8 mg every 2 weeks based on glycemic response and tolerability.
None Documented
None Documented
Terminal elimination half-life is approximately 2.4 hours after subcutaneous administration for immediate-release exenatide; however, BYDUREON (extended-release) exhibits a prolonged half-life of approximately 2 weeks (mean range 14-20 days) due to encapsulation in microspheres.
Terminal elimination half-life is 4–6 hours in patients with normal renal function; clinically, steady-state is reached within 24 hours.
Excreted primarily via renal proteolytic degradation; intact exenatide is eliminated renally. Renal clearance accounts for approximately 80% of total clearance; fecal elimination is negligible (<5%).
Renal: ~90% (30% unchanged, rest as inactive metabolites); fecal: ~10%.
Category C
Category C
Antidiabetic
Dopamine Agonist / Antidiabetic